CFM
BPMC

Catalyst Funds Management’s Blueprint Medicines BPMC Stock Holding History

Catalyst Funds Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-800
Closed -$75.9K – 1215
2024
Q1 		$75.9K Buy
+800
New +$68.6K 0.02% 464

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Catalyst Funds Management's BPMC Position: Q2 2024 in Review

Catalyst Funds Management sold out of Blueprint Medicines (BPMC) in Q2 2024, closing a stake of 800 shares — an estimated $75.9K sold.

Catalyst Funds Management first reported a position in BPMC in Q1 2024 and held it in 1 quarter. The position peaked at $75.9K in Q1 2024. 305 funds tracked by Wall St. Rank hold BPMC as of Q2 2024.

  • Catalyst Funds Management reported no remaining Blueprint Medicines position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 800 Blueprint Medicines shares in Q2 2024, an estimated $75.9K.
  • Catalyst Funds Management first reported a position in Blueprint Medicines in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Blueprint Medicines position peaked at $75.9K in Q1 2024.
  • 305 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.